Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1361755 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
The design, synthesis and biological evaluation of a novel series of isoindoline-based hydroxamates is described. Several analogs were shown to inhibit HDAC1 with IC50 values in the low nanomolar range and inhibit cellular proliferation of HCT116 human colon cancer cells in the sub-micromolar range. The cellular potency of compound 17e was found to have greater in vitro anti-proliferative activity than several compounds in late stage clinical trials for the treatment of cancer. The in vitro safety profiles of selected compounds were assessed and shown to be suitable for further lead optimization.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Michael Shultz, Jianmei Fan, Christine Chen, Young Shin Cho, Nicole Davis, Sheri Bickford, Kristen Buteau, Xueying Cao, Mats Holmqvist, Meier Hsu, Lei Jiang, Gang Liu, Qiang Lu, Chetan Patel, Joghee Raju Suresh, Mannangatti Selvaraj, Laszlo Urban,